Presentation ESC 2024 Continuation versus Interruption of Oral Anticoagulation during TAVI Presenter: Dirk-Jan van Ginkel August 31, 2024 REGISTER for free or LOG IN to view this content Clinical Cardiology Clinical Pharma Structural Heart Aortic Valve Heart Rhythm Pharma Presentation ESC 2024 Up Next Presentation ESC 2024 QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension Presenter: Stefano Taddei August 31, 2024 More slides + Presentation ESC 2024 DCB with rescue stenting versus intended stenting for de novo CAD: a multicenter, non-inferiority trial Presenter: Ling Tao September 02, 2024 Presentation ESC 2024 The efficacy of low-voltage-area ablation in patients with persistent atrial fibrillation: Results from a SUPPRESS-AF trial Presenter: Masaharu Masuda September 02, 2024 We Recommend
Presentation ESC 2024 QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension Presenter: Stefano Taddei August 31, 2024
Presentation ESC 2024 DCB with rescue stenting versus intended stenting for de novo CAD: a multicenter, non-inferiority trial Presenter: Ling Tao September 02, 2024
Presentation ESC 2024 The efficacy of low-voltage-area ablation in patients with persistent atrial fibrillation: Results from a SUPPRESS-AF trial Presenter: Masaharu Masuda September 02, 2024